martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 12, 2025

Why I'm Expecting A Year-End Rally, And Another Big Year Next Year!

View original at finance.yahoo.com
Why I'm Expecting A Year-End Rally, And Another Big Year Next Year! Hard to believe there’s only 3½ weeks left in the year. But what a year it’s been…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Expecting year-end rally and another big year next year

    80% confidence
  • December has a 77.8% likelihood of finishing higher in post-election years since 1950

    80% confidence
  • AI data center market could grow to $1 trillion by 2030

    80% confidence
  • Fed maintains outlook for another rate cut next year

    80% confidence
  • AI will revolutionize every industry, from healthcare to transportation

    80% confidence
  • Half of a stock's price movement can be attributed to the group that it's in

    80% confidence
  • AI market is faster than anything we've seen before

    80% confidence
  • We are at the beginning of a new computing era

    80% confidence
  • Stocks with Zacks Rank #1 Strong Buy have beaten the market in 29 of the last 37 years (78% win ratio) with average annual return of more than 24% per year

    80% confidence
  • AI is the most powerful technology force of our time

    80% confidence
  • Could possibly see 5 years or more of boom times similar to dot-com era

    80% confidence
  • AMD could grow by 35% a year for the next 3-5 years because of AI demand

    80% confidence
  • Demand for AI is insatiable

    80% confidence
  • Stocks in the top 50% of Zacks Ranked Industries outperform those in the bottom 50% by a factor of 2 to 1

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com